Acumen Pharmaceuticals, Inc. (ABOS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Acumen Pharmaceuticals reported revenue of $0. Net income was -$121.3M, or -$2.00 per diluted share. Operating activities generated -$115.5M of cash, leaving -$115.6M of free cash flow. At fiscal year end, Acumen Pharmaceuticals held $122.8M in total assets against $52.4M in total liabilities, including $54.0M of cash and equivalents.
Open the full interactive Acumen Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Acumen Pharmaceuticals Key Stats
| Share Price | $1.82 |
|---|---|
| Market Cap | $131.1M |
| 52-Week Range | $1.55 – $3.37 |
| Shares Outstanding | 72.3 million (basic, 2026 Q2) |
Acumen Pharmaceuticals Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$19.6M | -$45.2M | -$61.1M | -$114.0M | -$123.8M |
| Pre-Tax Income | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M |
| Diluted EPS | -$5.02 | -$1.06 | -$1.08 | -$1.71 | -$2.00 |
Acumen Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$26.5M | -$25.1M | -$20.7M | -$32.7M |
| Diluted EPS | -$0.44 | -$0.42 | -$0.33 | -$0.45 |
Acumen Pharmaceuticals Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $122.2M | — | $66.9M | $35.6M | $54.0M |
| Current Assets | $198.7M | $180.3M | $246.6M | $178.3M | $122.3M |
| Total Assets | $230.3M | $196.6M | $310.1M | $239.0M | $122.8M |
| Current Liabilities | — | $7.8M | $13.0M | $27.6M | $30.0M |
| Total Long-Term Debt | — | — | $29.9M | $29.4M | $22.4M |
| Total Liabilities | $5.1M | $7.8M | $43.2M | $57.2M | $52.4M |
| Shareholders' Equity | $225.2M | $188.8M | $267.0M | $181.8M | $70.4M |
Acumen Pharmaceuticals Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$18.0M | -$35.2M | -$43.1M | -$86.2M | -$115.5M |
| Cash From Investing | -$104.1M | $39.2M | -$171.7M | $48.0M | $133.9M |
| Cash From Financing | $200.5M | $3.9M | $151.8M | $6.9M | -$34,000 |
| Free Cash Flow | -$18.0M | -$35.3M | -$43.1M | -$86.2M | -$115.6M |
Figures from Acumen Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Acumen Pharmaceuticals financials page for every line item.
Acumen Pharmaceuticals Company Profile
| Ticker | ABOS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Newton, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001576885 |
Frequently Asked Questions
What was Acumen Pharmaceuticals' revenue in fiscal 2025?
Acumen Pharmaceuticals (ABOS) reported revenue of $0 for fiscal 2025.
What is Acumen Pharmaceuticals' annual revenue history?
Acumen Pharmaceuticals' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Acumen Pharmaceuticals' net income in fiscal 2025?
Acumen Pharmaceuticals reported net income of -$121.3M for fiscal 2025.
What was Acumen Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Acumen Pharmaceuticals' diluted EPS was -$2.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Acumen Pharmaceuticals generate in fiscal 2025?
Acumen Pharmaceuticals generated -$115.6M of free cash flow in fiscal 2025.
What was Acumen Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Acumen Pharmaceuticals reported revenue of $0.
How much debt does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals reported $22.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Acumen Pharmaceuticals are outstanding?
Acumen Pharmaceuticals reported a weighted average of 72.3 million basic shares outstanding in 2026 Q2.
What is Acumen Pharmaceuticals' market cap?
Based on its latest closing price, Acumen Pharmaceuticals (ABOS) has a market capitalization of about $131.1M.
When does Acumen Pharmaceuticals' fiscal year end?
Acumen Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Acumen Pharmaceuticals headquartered?
Acumen Pharmaceuticals lists its business address in Newton, Massachusetts in its SEC filings.
Acumen Pharmaceuticals Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →